Flow Cytometric Analysis of Benign and Malignant Tumors

流式细胞术单元通过以下方式为NCI临床方案提供广泛支持： 为接受NCI临床治疗的患者提供白血病和淋巴瘤的诊断检测 方案或进行测试以确定所述方案的合格性。流动 流式细胞术单位提供血液、骨髓、细针的临床流式细胞术评价 抽吸物、组织活检和体液用于NCI患者的血淋巴样瘤形成。的 由流式细胞术单元进行的大多数流式细胞术检测涉及检测 微小残留病（患者在治疗前在外部机构治疗后的状态） 根据NCI方案招募）和测量特定肿瘤细胞特征， 各种临床方案。该股的重大努力是致力于提供许多 商业实验室不提供的独特方案规定的测定。流动 细胞计数单位还积极参与国家卫生研究院工作人员和医学界的教育， 流式细胞术在医疗实践中的正确应用。流式细胞术单元为NCI临床方案提供广泛的支持， 为接受NCI临床治疗的患者提供白血病和淋巴瘤的诊断检测 方案或进行测试以确定所述方案的合格性。流动 流式细胞术单位提供血液、骨髓、细针的临床流式细胞术评价 抽吸物、组织活检和体液用于NCI患者的血淋巴样瘤形成。的 由流式细胞术单元进行的大多数流式细胞术检测涉及检测 微小残留病（患者在治疗前在外部机构治疗后的状态） 根据NCI方案招募）和测量特定肿瘤细胞特征， 各种临床方案。该股的重大努力是致力于提供许多 商业实验室不提供的独特方案规定的测定。流动 细胞计数单位还积极参与国家卫生研究院工作人员和医学界的教育， 在医学实践中，流式细胞术的适当应用是很大的。

The Flow Cytometry Unit provides extensive support for NCI clinical protocols by providing diagnostic testing for leukemia and lymphoma in patients either on NCI clinical protocols or undergoing testing to determine eligibility for said protocols. The Flow Cytometry Unit provides clinical flow cytometric evaluation of blood, bone marrow, fine needle aspirates, tissue biopsies and body fluids for hematolymphoid neoplasia in NCI patients. The majority of flow cytometric testing performed by the Flow Cytometry Unit involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. Significant effort in the unit is devoted to delivery of numerous unique protocol mandated assays that are not offered by commercial laboratories. The Flow Cytometry Unit is also actively engaged in education of the NIH staff and medical community at large in the proper utility of flow cytometry in medical practice.The Flow Cytometry Unit provides extensive support for NCI clinical protocols by providing diagnostic testing for leukemia and lymphoma in patients either on NCI clinical protocols or undergoing testing to determine eligibility for said protocols. The Flow Cytometry Unit provides clinical flow cytometric evaluation of blood, bone marrow, fine needle aspirates, tissue biopsies and body fluids for hematolymphoid neoplasia in NCI patients. The majority of flow cytometric testing performed by the Flow Cytometry Unit involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. Significant effort in the unit is devoted to delivery of numerous unique protocol mandated assays that are not offered by commercial laboratories. The Flow Cytometry Unit is also actively engaged in education of the NIH staff and medical community at large in the proper utility of flow cytometry in medical practice.